Skip to Main content Skip to Navigation
Journal articles

Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes

Abstract : The physiological and pathophysiological relevance of the angiotensin II type 1 (AT1) G protein-coupled receptor no longer needs to be proven in the cardiovascular system. The renin–angiotensin system and the AT1 receptor are the targets of several classes of therapeutics (such as angiotensin converting enzyme inhibitors or angiotensin receptor blockers, ARBs) used as first-line treatments in cardiovascular diseases. The importance of AT1 in the regulation of the cerebrovascular system is also acknowledged. However, despite numerous beneficial effects in preclinical experiments, ARBs do not induce satisfactory curative results in clinical stroke studies. A better understanding of AT1 signaling and the development of biased AT1 agonists, able to selectively activate the β-arrestin transduction pathway rather than the Gq pathway, have led to new therapeutic strategies to target detrimental effects of AT1 activation. In this paper, we review the involvement of AT1 in cerebrovascular diseases as well as recent advances in the understanding of its molecular dynamics and biased or non-biased signaling. We also describe why these alternative signaling pathways induced by β-arrestin biased AT1 agonists could be considered as new therapeutic avenues for cerebrovascular diseases.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-lorraine.fr/hal-03287839
Contributor : Michel Boisbrun <>
Submitted on : Thursday, July 15, 2021 - 9:58:35 PM
Last modification on : Friday, September 10, 2021 - 1:04:03 PM

Links full text

Identifiers

Citation

Céline Delaitre, Michel Boisbrun, Sandra Lecat, François Dupuis. Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes. International Journal of Molecular Sciences, MDPI, 2021, 22 (13), pp.6738. ⟨10.3390/ijms22136738⟩. ⟨hal-03287839⟩

Share

Metrics

Record views

32